Welcome to our dedicated page for Cardiol Therapeu news (Ticker: CRDL), a resource for investors and traders seeking the latest updates and insights on Cardiol Therapeu stock.
Cardiol Therapeutics Inc. reports clinical, financing, and corporate updates as a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead oral small-molecule candidate, CardiolRx, modulates inflammasome pathway activation associated with inflammation and fibrosis in pericarditis, myocarditis, and heart failure.
Recurring developments include the MAVERIC program in recurrent pericarditis, the completed ARCHER Phase II study in acute myocarditis, peer-reviewed publication of clinical data, U.S. trial-network updates, intellectual-property disclosures, and development of CRD-38 for heart failure and other inflammatory heart diseases. Company news also covers bought deal financings, common share and warrant offerings, annual operating updates, and healthcare conference presentations.
Cardiol Therapeutics (NASDAQ:CRDL) will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ in New York.
The session is scheduled for May 19, 2026 at 1:30 p.m. EDT, with a live webcast and a replay available for 90 days.
Cardiol Therapeutics (NASDAQ: CRDL) announced Phase II MAvERIC results have been accepted for publication in the Journal of the American Heart Association.
The peer-reviewed report links CardiolRx treatment to rapid, sustained reductions in pericarditis pain and inflammation, a substantial reduction in yearly pericarditis episodes, a favorable safety profile, and supports the ongoing pivotal Phase III MAVERIC trial, which has surpassed 75% enrollment.
Cardiol Therapeutics (NASDAQ: CRDL) announced expansion of its pivotal Phase III MAVERIC trial in the U.S., planning up to seven additional clinical centers to reach an anticipated total of 25 sites.
Patient enrollment has reached 75%, with target recruitment expected by end of Q2 2026 but potentially extending into Q3 2026. MAVERIC is a randomized, placebo-controlled trial of CardiolRx™ designed with FDA alignment and intended to support a future NDA.
Cardiol Therapeutics (NASDAQ: CRDL) announced a live interview with Barchart on X today, April 14, 2026, at 12:00 PM EDT featuring CEO David Elsley. Topics include the pivotal Phase III MAVERIC trial for recurrent pericarditis, published Phase II ARCHER myocarditis results, and next-gen drug CRD-38.
Investors can join live at x.com/Barchart; a full recording will be posted on Cardiol's X channel (@CardiolRx) and Barchart's channel after the event.
Cardiol Therapeutics (NASDAQ: CRDL) reported year-end 2025 operational progress: initiated pivotal Phase III MAVERIC in recurrent pericarditis (>50% enrolled; full enrollment expected Q2 2026), reported positive Phase II ARCHER results (LV mass reduction of -9.2g, p=0.0117), advanced CRD-38 toward IND/Phase I, received a U.S. patent allowance through Oct 2040, strengthened its board, and raised $31M in financings, funding operations into Q4 2027.
Key priorities include completing MAVERIC enrollment, initiating CRD-38 clinical work, and pursuing strategic partnerships.
Cardiol Therapeutics (NASDAQ: CRDL) will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 4, 2026 at 10:30 a.m. EST.
A live webcast and a replay will be available under Events & Presentations in the Investors section of the company website.
Cardiol Therapeutics (NASDAQ: CRDL) announced publication of its Phase II ARCHER study in ESC Heart Failure on February 10, 2026. The randomized, double‑blind, placebo‑controlled trial in 109 patients reported a significant reduction in left ventricular mass versus placebo (-9.2 g; p=0.0117), decreased left atrial remodelling, favorable trends in myocardial inflammation markers, and a safety/tolerability profile. The authors and company highlight relevance of these biological signals to Cardiol's ongoing pivotal Phase III MAVERIC trial in recurrent pericarditis, citing myocarditis–pericarditis overlap and potential implications for inflammation‑driven structural heart damage.
Cardiol Therapeutics (NASDAQ: CRDL) closed a private placement on January 23, 2026, raising $14.85 million through the issuance of 11,423,078 Units at $1.30 per Unit, including full exercise of the over‑allotment option. Each Unit comprises one common share and one‑half of a warrant; each whole warrant is exercisable at $1.75 for 24 months. Canaccord Genuity acted as sole underwriter and the company paid a 6% cash commission. Net proceeds are intended for research and clinical development, general and administrative expenses, working capital, and other expenses. The offering was completed as a private placement under Canadian prospectus exemptions and the securities are not registered in the United States.
Cardiol Therapeutics (NASDAQ: CRDL) entered a bought deal private placement to issue 10,384,616 units at $1.30 per unit for gross proceeds of $13.5 million, with an underwriter option to sell up to an additional 1,038,462 units to raise up to $1.35 million. Each unit includes one common share and one-half warrant; each full warrant exercisable at $1.75 for 24 months.
The offering is expected to close on or about January 23, 2026, is subject to TSX approvals and customary conditions, and the company intends to use net proceeds to advance research and clinical development and for general corporate purposes.
Cardiol Therapeutics (NASDAQ: CRDL) announced it has surpassed 50% patient enrollment in MAVERIC, its pivotal Phase III randomized, double-blind, placebo-controlled trial of CardiolRx for recurrent pericarditis. More than 15 U.S. cardiovascular centers are actively enrolling, with additional sites in Europe and Canada being activated. MAVERIC plans ~110 patients across ~25 centers, a primary endpoint of freedom from new recurrent pericarditis at 6 months, and secondary endpoints including pericarditis pain days, pain score changes, and CRP. Full enrollment is expected in Q2 2026.